Proteasome Regulator Marizomib (NPI-0052) Exhibits Prolonged Inhibition, Attenuated Efflux, and Greater Cytotoxicity than Its Reversible Analogs

The present study was undertaken to compare the cellular transport characteristics of [3H]NPI-0052 (1R,4R,5S)-4-(2-chloroethyl)-1-((S)-((S)-cyclohex-2-enyl)(hydroxy)methyl)-5-methyl-6-oxa-2-azabicyclo[3.2.0]heptane-3,7-dione (marizomib; salinosporamide A) and [3H]NPI-0047 (1R,4R, 5S)-1-((S)-((S)-cyclohex-2-enyl)(hydroxy)methyl)-4-ethyl-5-methyl-6-oxa-2-azabicyclo[3.2.0]heptane-3,7-dione in RPMI 8226 multiple myeloma and PC-3 prostate adenocarcinoma cells to determine whether these properties explain differences in the cytotoxic potencies of these chemical analogs. The results indicate that marizomib, which possesses a chemical-leaving group, is more cytotoxic to both cell lines and inhibits proteasome activity more completely at lower concentrations than NPI-0047, a nonleaving-group analog. Moreover, it was found that both compounds accumulate in these cells by simple diffusion and the same carrier-mediated transport system. Although the rate of uptake is similar, the cellular efflux, which does not seem to be mediated by a major ATP-binding cassette (ABC)-efflux transporter, is more rapid for NPI-0047 than for marizomib. Experiments revealed that the irreversible binding of marizomib to the proteasome is responsible for its slower efflux, longer duration of action, and greater cytotoxicity compared with NPI-0047. The discovery that major ABC transporters of the multidrug resistance-associated protein family do not seem to be involved in the accumulation or removal of these agents suggests they may not be affected by multidrug resistance mechanisms during prolonged administration.

[1]  P. Williams,et al.  New cytotoxic salinosporamides from the marine Actinomycete Salinispora tropica. , 2005, The Journal of organic chemistry.

[2]  Hiroshi Yasui,et al.  A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib. , 2005, Cancer cell.

[3]  S. Neuteboom,et al.  Structure-activity relationship studies of salinosporamide A (NPI-0052), a novel marine derived proteasome inhibitor. , 2005, Journal of medicinal chemistry.

[4]  W. Dalton,et al.  The proteasome. , 2004, Seminars in oncology.

[5]  Jian Zhang,et al.  The establishment of two paclitaxel‐resistant prostate cancer cell lines and the mechanisms of paclitaxel resistance with two cell lines , 2007, The Prostate.

[6]  J. Zalcberg,et al.  MRP1 not MDR1 gene expression is the predominant mechanism of acquired multidrug resistance in two prostate carcinoma cell lines , 2000, Prostate Cancer and Prostatic Diseases.

[7]  A. Goldberg,et al.  The Caspase-like Sites of Proteasomes, Their Substrate Specificity, New Inhibitors and Substrates, and Allosteric Interactions with the Trypsin-like Sites* , 2003, Journal of Biological Chemistry.

[8]  V. Macherla,et al.  Stereoselective enzymatic reduction of keto-salinosporamide to (−)-salinosporamide A (NPI-0052) , 2007 .

[9]  T. Hideshima,et al.  Molecular mechanisms of novel therapeutic approaches for multiple myeloma , 2002, Nature Reviews Cancer.

[10]  C. Gui,et al.  Effect of pregnane X receptor ligands on transport mediated by human OATP1B1 and OATP1B3. , 2008, European journal of pharmacology.

[11]  D. Chauhan,et al.  Proteasome inhibition in multiple myeloma: therapeutic implication. , 2005, Annual review of pharmacology and toxicology.

[12]  M. Groll,et al.  Snapshots of the fluorosalinosporamide/20S complex offer mechanistic insights for fine tuning proteasome inhibition. , 2009, Journal of medicinal chemistry.

[13]  V. Stella,et al.  A mechanistic and kinetic study of the beta-lactone hydrolysis of Salinosporamide A (NPI-0052), a novel proteasome inhibitor. , 2007, Journal of pharmaceutical sciences.

[14]  S. Neuteboom,et al.  Leaving groups prolong the duration of 20S proteasome inhibition and enhance the potency of salinosporamides. , 2008, Journal of medicinal chemistry.

[15]  A. Sartorelli,et al.  Transport of fluorescein in MDCKII-MRP1 transfected cells and mrp1-knockout mice. , 2001, Biochemical and biophysical research communications.

[16]  Sy Teisan,et al.  Aureoverticillactam, a novel 22-atom macrocyclic lactam from the marine actinomycete Streptomyces aureoverticillatus. , 2004, Journal of natural products.

[17]  K. Anderson.  Bortezomib therapy for myeloma. , 2004, Current hematology reports.

[18]  J. Adams.  The proteasome: a suitable antineoplastic target , 2004, Nature Reviews Cancer.

[19]  Sy Teisan,et al.  Salinosporamides D-J from the marine actinomycete Salinispora tropica, bromosalinosporamide, and thioester derivatives are potent inhibitors of the 20S proteasome. , 2007, Journal of natural products.

[20]  K. Anderson.  Stem cell transplantation for myeloma. , 2004, Current hematology reports.

[21]  R. Huber,et al.  Crystal structures of Salinosporamide A (NPI-0052) and B (NPI-0047) in complex with the 20S proteasome reveal important consequences of beta-lactone ring opening and a mechanism for irreversible binding. , 2006, Journal of the American Chemical Society.

[22]  William Fenical,et al.  Salinosporamide A: a highly cytotoxic proteasome inhibitor from a novel microbial source, a marine bacterium of the new genus salinospora. , 2003, Angewandte Chemie.